RxDoctor Payments DataLook up a doctor →

Joelle Hamilton, MD

Medical Oncology · Homewood, ALNPI 1578574851

Payments from drug & device makers

$2,203,275in general payments, 2019–2025

Across 1,494 payments — averaging $1474.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1.1M
  • Janssen Research & Development, LLC$509K
  • Sumitomo Pharma America, Inc.$234K
  • AstraZeneca$229K
  • Johnson & Johnson$117K
  • Pfizer$25K
  • plus $18K from 32 others

What the payments were for

  • Consulting fees$98,68127%
  • Speaking & faculty fees$217,79760%
  • Travel & lodging$31,9249%
  • Food & beverage$11,9563%
  • Education$6040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,203,275 in reported general payments places this provider in the 95th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$1,198,158
Medicare patients
277
Services billed
29,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide357$5,028,122
XtandiEnzalutamide338$4,439,826
NubeqaDarolutamide322$4,034,447
OrgovyxRelugolix784$2,104,924
Abiraterone Acetate362$480,670
LynparzaOlaparib29$438,093
AkeegaNiraparib/Abiraterone19$350,448
TalzennaTalazoparib Tosylate17$302,026
CabometyxCabozantinib S-Malate11$257,456
Alendronate Sodium273$2,490
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$1,625
Prednisone324$1,409
Potassium Chloride74$1,025
Oxycodone Hcl41$870
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen34$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Akeega$116,747$5,378,570376 claims
Astellas Pharma US IncXtandi$1,236$4,439,826338 claims
BayerNubeqa$1,071,925$4,034,447322 claims
Sumitomo Pharma America, Inc.Orgovyx$233,646$2,104,924784 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,508$480,670362 claims
AstraZenecaLynparza$228,768$438,09329 claims
PfizerTalzenna$24,960$302,02617 claims
Exelixis Inc.Cabometyx$105$257,45611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 medical oncology providers in Alabama.

Other medical oncology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →